Breye Therapeutics raises €67.5M Series A for oral eye drug

Breye Therapeutics, a clinical-stage biotech in Hørsholm, Denmark, has raised an over-subscribed €67.5M Series A co-led by new investor Mission BioCapital and existing backer Novo Holdings, to take danegaptide, its oral drug for early diabetic retinopathy, into a Phase 2 trial in 2027.

The standard of care in diabetic eye disease is an injection into the eyeball, given late, once vision is already under threat. Hard to think of a louder invitation to build something better – and this week the answer came not from Boston but from Hørsholm, a coastal town north of Copenhagen. Below, I lay out the round, the science, and the four investors we keep meeting on Nordic cap tables this week.

Nine investors for an over-subscribed round

Breye announced the €67.5M Series A on 29 September 2026. Mission BioCapital, a US life-science firm with offices in Cambridge, Massachusetts and San Francisco, co-led as a new investor alongside existing backer Novo Holdings. Existing investor Sound Bioventures returned, joined by a bench of new names: the Ljungström family office, Innovestor Life Science, EIFO – Denmark’s export and investment fund – Catalyze Capital, Modi Ventures and Pappas Capital.

The money has one headline job: moving danegaptide into a randomised Phase 2 trial in patients with non-proliferative diabetic retinopathy, planned for 2027 and designed to deliver clinical proof of concept. The rest matures the earlier pipeline toward IND-enabling studies. Mission BioCapital’s Robert Blazej and Lukas Ljungström of the family office join the board.

The financing “reflects strong confidence in Breye’s vision, strategy, and pipeline”, CEO Ulrik Mouritzen said in the announcement.

A pill where the needle rules

Breye Therapeutics, founded in 2019, is built on an idea about timing. Today’s treatments, led by anti-VEGF injections into the eye, mostly arrive at the later stages of the disease, when retinal damage is well advanced. Danegaptide, a first-in-class oral small molecule, aims years earlier: the company says it stabilises the retinal vasculature, protecting capillaries from the breakdown and vascular leakage that high glucose levels set off.

The Phase 1b, completed in 2025, showed good tolerability and early signs of clinical activity, with reduced vascular leakage on retinal imaging, per the announcement. Behind danegaptide sit a P2X7 receptor antagonist for intermediate age-related macular degeneration and earlier glaucoma candidates with neuroprotective effects.

“Danegaptide has potential to address major unmet need in diabetic retinopathy by offering highly effective, non-invasive treatment,” said Jørgen Søberg Petersen, senior partner at Novo Holdings. Non-invasive is doing quiet work in that sentence: a daily pill a GP can prescribe is a different product category from a needle an ophthalmologist administers.

A $10.7bn market treated too late

So why does an eye pill command one of the week’s biggest European rounds? Scale, mostly. Roughly 130 million people worldwide live with diabetic retinopathy, per the company’s announcement. The diabetic retinopathy market is worth $10.71bn in 2026 and headed for $14.52bn by 2031, a 6.27% CAGR (Mordor Intelligence, July 2026) – and, the company’s case goes, it is served late, at the proliferative stage where the approved tools live. An oral drug for the early stage would not take share from the injections; it would open a market upstream of them.

For scale in our own fundraising data: AnaCardio’s €62.5M Series B for an oral heart-failure drug and Aptadir’s €40M seed for RNA therapeutics were the week’s other heavyweight European biotech rounds. Breye tops both.

Four names, two cap tables, one week

Here is the pattern worth filing. Novo Holdings, the Ljungström family office, Innovestor Life Science and Sound Bioventures all appear again in AnaCardio’s Series B, announced one day after Breye’s round, per our records. Two Nordic companies, two oral small molecules aimed at diseases currently managed with needles – or not managed at all – and four investors backing both. EIFO, meanwhile, shows up twice in the same week: here and in Onomondo’s €100M growth round.

What we are seeing is a compact Nordic life-science bench that moves as a bloc – family offices, specialist funds and state capital syndicating together, then pulling in a US co-lead for reach. The good news is that this is exactly the structure Europe’s biotech scene has long been accused of lacking: patient local capital able to price a Series A at home instead of waiting for Boston to do it. What to watch: whether the same names reconvene for the Series B, and whether the Phase 2, enrolling in 2027, reads out the way the Phase 1b imaging hinted.

Europe does not lack retinal science; it has lacked the cheque-writers to keep it here. This week, Hørsholm got both. Watch the 2027 trial.